These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 19707452)

  • 1. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
    Kaminetzky D; Hymes KB
    Biologics; 2008 Dec; 2(4):717-24. PubMed ID: 19707452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.
    Lansigan F; Stearns DM; Foss F
    Cancer Manag Res; 2010 Feb; 2():53-9. PubMed ID: 21188096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracorporeal photophoresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cutaneous T cell lymphoma: current status and future directions.
    Apisarnthanarax N; Talpur R; Duvic M
    Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach.
    Al Hothali GI
    Int J Health Sci (Qassim); 2013 Jun; 7(2):220-39. PubMed ID: 24421750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study.
    Querfeld C; Nelson WW; Gor D; Pashos CL; Doan QV; Turini M; Angello JT; Geskin LJ
    Dermatol Ther (Heidelb); 2022 Dec; 12(12):2781-2795. PubMed ID: 36284059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
    Olsen E; Duvic M; Frankel A; Kim Y; Martin A; Vonderheid E; Jegasothy B; Wood G; Gordon M; Heald P; Oseroff A; Pinter-Brown L; Bowen G; Kuzel T; Fivenson D; Foss F; Glode M; Molina A; Knobler E; Stewart S; Cooper K; Stevens S; Craig F; Reuben J; Bacha P; Nichols J
    J Clin Oncol; 2001 Jan; 19(2):376-88. PubMed ID: 11208829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
    Chin KM; Foss FM
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
    Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
    J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
    Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
    Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions for mycosis fungoides.
    Valipour A; Jäger M; Wu P; Schmitt J; Bunch C; Weberschock T
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD008946. PubMed ID: 32632956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
    Duvic M
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
    Whittaker SJ; Foss FM
    Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
    Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
    Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
    J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions for mycosis fungoides.
    Weberschock T; Strametz R; Lorenz M; Röllig C; Bunch C; Bauer A; Schmitt J
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008946. PubMed ID: 22972128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and emerging treatment strategies for cutaneous T-cell lymphoma.
    Lansigan F; Foss FM
    Drugs; 2010 Feb; 70(3):273-86. PubMed ID: 20166766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.